Co Losartan · DIN 02354829 · 25mg · tablet
General benefit; Health Canada lists this DIN as Cancelled post market since 2019-08-07 — choose a marketed DIN from the same-category list.Discontinued 2019-08-07 · checked 2026-09-02
StatusGeneral benefit; Health Canada lists this DIN as Cancelled post market since 2019-08-07 — choose a marketed DIN from the same-category list.
Write on scriptno code needed; Health Canada lists this DIN as Cancelled post market since 2019-08-07 — choose a marketed DIN from the same-category list.
Patient paysPatient pays: program not supplied; amount cannot be determined.
Private plan unknown: ask. If yes, check its coverage and payer coordination; if no, see the public routes below.
Brand vs generic price
Lowest DBP recovery rule under medically necessary no-substitution claims:
6.2 Medically Necessary "No Substitution" Claims
The Side Effect Reporting Form will not have to be renewed. However, the
pharmacy must maintain a copy of the prescription that contains a direction that
there be no substitution and the required Health Canada Side Effect Reporting Form
(completed and signed by the prescriber). The prescriber must write “No
Substitution” or “No Sub” on renewal or subsequent new written prescriptions, and
indicate “No Substitution” on subsequent new oral prescriptions. The dispenser will
be reimbursed the DBP plus a mark-up and the lesser of the posted usual and
customary fee or the ODB dispensing fee minus the applicable ODB co-payment
amount. Where a completed Side Effect Reporting Form is not available at the
pharmacy during an inspection, the difference between the cost of the higher-cost
product and the lowest DBP listed for the interchangeable category will be
recovered.
(ontario.ca, Revision #17; 2026-08-03 ↗)
6.2 Medically Necessary "No Substitution" Claims
The Ministry will provide reimbursement of a higher-cost interchangeable product in
medically necessary circumstances where a patient has experienced a significant
adverse reaction with two (2) lower-cost interchangeable drug products, where
available. When a prescriber identifies a patient for which it is medically necessary
that a higher cost interchangeable product be provided, the prescriber must:
• Complete, sign and forward to the pharmacist a copy of the Health Canada
side effect reporting form for each lower-cost interchangeable drug product
trialed (Side Effect Reporting Form[s]); and
• Write “No Substitution” or “No Sub” on a written prescription or indicate “No
Substitution” to the pharmacist in the case of a verbal prescription.
The prescriber should keep a copy of the completed form in the patient’s record for
future use and reference.
In the case of a written prescription, when the pharmacist or dispensing physician
receives a prescription with the written notation “No Substitution” or “No Sub”,
reimbursement will be provided for the higher-cost interchangeable product only if
the prescription is accompanied by a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed.
This form must be completely filled out noting the details of the adverse reaction
and signed by the prescriber.
In the case of a verbal prescription, the prescriber must satisfy the operator of the
pharmacy or dispensing physician that a completed Health Canada Side Effect
Reporting Form for each of the lower-cost interchangeable drug products trialed
has been completed and signed by the prescriber. A written record of this verbal
prescription and the completed Health Canada Side Effect Reporting Form must be
received by the pharmacy prior to claim submission.
Upon receipt, the pharmacist must:
• Fax, submit online or mail the completed and signed form to Health Canada’s
Canada Vigilance Program; and
• Retain his or her copy of the completed and signed Side Effect Reporting
Form.
(ontario.ca, Revision #17; 2026-08-03 ↗)
1 brand, same coverage
Co Losartan · DIN 02354829
Manufacturer: Cobalt Pharmaceuticals Company; listing date 2012-03-26
Health Canada: Cancelled post market since 2019-08-07 · brand ACT LOSARTAN · ATC C09CA01 LOSARTAN · form Tablet · route Oral · ingredients LOSARTAN POTASSIUM 25 MG · company Actavis pharma company · schedule Prescription
Ministry pays: $0.3147 per source unit.
Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.
Formulary data: Ontario extract of Aug 26, 2026 · Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84000 · Verify on the e-Formulary ↗ (DIN 02354829)
Source record
DIN 02354829: Co Losartan
Raw flags: chronicUseMed=Y, sec3=Y
Item: 240800212; group id 335; item number 0757; lccId None; manufacturer id COB
Source form: Tab; strength: 25mg
Recorded listing: General benefit; chronic-use medication (100-day supply rule, dispensing-fee limit)
Source prices (unrounded): $0.3148; ministry $0.3147
Source: ODB odb-formulary-ed43-extract-2026-08-26.xml extract_date=2026-08-26 DIN=02354829
Health Canada DPD extract of Sep 2, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=84000
Interchangeable products
Apo-Losartan · DIN 02379058 · $0.3147
Auro-Losartan · DIN 02403323 · $0.3147
Bio-Losartan · DIN 02445964 · $0.3147
Cozaar · DIN 02182815 · $0.3147
Jamp-Losartan · DIN 02398834 · $0.3147
Losartan · DIN 02388790 · $0.3147
Losartan · DIN 02388863 · $0.3147
Mint-Losartan · DIN 02405733 · $0.3147
PMS-Losartan · DIN 02309750 · $0.3147
Ran-Losartan · DIN 02404451 · $0.3147
Sandoz Losartan · DIN 02313332 · $0.3147
Septa-Losartan · DIN 02424967 · $0.3147
Teva-Losartan · DIN 02380838 · $0.3147
Shortage status: discontinued (2018-02-28, reported by ACTAVIS PHARMA COMPANY); reports as of 2026-09-13T08:10:21.292534+00:00 (Health Product Shortages Canada)
Source: https://healthproductshortages.ca/search?term=02354829
Shortage record checked 2026-09-13T08:10:21.292534+00:00
Health Canada lists this DIN as Cancelled post market since 2019-08-07 — choose a marketed DIN from the same-category list.